《大行報告》摩通下調申洲(02313.HK)目標價至220元 評級「增持」
摩根大通發表報告表示,申洲國際(02313.HK)股價由5月份股價高位至今已累跌約20%,因市場擔心公司海外廠房受到疫情所拖累。
該行估計申洲國際今年上半年盈利大致持平,料下半年可重振增長動力,而越南社交距離措施影響有限,公司會繼續利用中國內地與柬埔寨廠房降低影響,加上公司有效管理措施,相信公司受疫情影響會較同業微。
該行降申洲國際2021至2023年盈利2至7%,目標價由228元降至220元,此按現金流折現率作估值,相當預測市盈率33倍,評級「增持」,對公司維持樂觀,相信市佔率可繼續錄增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.